Study of GPC-3 CAR-T Cells in Treating With Hepatocellular Carcinoma
NCT ID: NCT05620706
Last Updated: 2022-11-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
20 participants
INTERVENTIONAL
2022-11-01
2028-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
GPC3-targeted CAR-T Cell for Treating GPC3 Positive Advanced HCC
NCT04121273
GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma
NCT05926726
GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
NCT03198546
CAR-T Cell Immunotherapy for HCC Targeting GPC3
NCT02723942
Novel GPC3 CAR-T Cell Therapy for Hepatocellular Carcinoma
NCT05344664
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment group
GCP3 CAR-T cells
GPC3 CAR-T cells
patients treated with GPC3 CAR-T cells
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GPC3 CAR-T cells
patients treated with GPC3 CAR-T cells
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients with advanced hepatocellular carcinoma (HCC) diagnosed by histopathology or cytology, who are not suitable for surgery or local treatment (including ablation therapy, interventional therapy and radiotherapy), and who have experienced progress or intolerance after receiving standard treatment in the past;
3. Patients who have been terminated for more than 28 days due to previous ineffective PD-1 monoclonal antibody treatment;
4. At least one target lesion that can be evaluated stably according to RECIST 1.1 standard is defined as: the longest diameter of non lymph node lesions ≥ 10mm, or the short diameter of lymph node lesions ≥ 15mm; Intrahepatic lesions require enhanced imaging in arterial phase;
5. Tumor tissue samples were positive for GPC3 by immunohistochemistry (IHC);
6. Grade C according to Barcelona liver cancer grading standard (BCLC) or Grade B which is not suitable for local treatment/progression of local treatment;
7. Estimated survival time \> 12 weeks;
8. Cirrhotic state Child Pugh score Grade A
9. ECOG physical status score 0\~1;
10. If the patient is HBsAg positive or HBcAb positive, HBV-DNA\<200IU/ml. HBsAg positive patients must receive antiviral treatment according to the Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2015);
11. Single vein access;
12. Blood routine test: WBC ≥ 2.5 × 109/L， PLT≥60 × 109/L， Hb≥9.0 g/dL，LY≥0.4 × 109/L；
13. Blood biochemistry: serum Alb ≥ 30 g/L, serum lipase and amylase ≤ 1.5 ULN, serum creatinine ≤ 1.5 ULN and endogenous creatinine clearance rate ≥ 40mL/min, ALT ≤ 5ULN, AST ≤ 5ULN, total bilirubin ≤ 2.5ULN, prothrombin time extension ≤ 4s;
14. The women of childbearing age must carry out serum pregnancy test within the screening period and 14 days before starting the study medication, and the result is negative. They are willing to use reliable methods of contraception during the test period (within 12 months (M12) after cell infusion); For male subjects whose partners are women of childbearing age, they should have undergone sterilization or agree to use reliable methods of contraception during the trial
15. Be able to understand and sign the informed consent form
HBsAg positive patients must receive antiviral treatment according to the Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2015);
11\. Single vein access;
12\. Blood routine test: WBC ≥ 2.5 × 109/L， PLT≥60 × 109/L， Hb≥9.0 g/dL，LY≥0.4 × 109/L；
13\. Blood biochemistry: serum Alb ≥ 30 g/L, serum lipase and amylase ≤ 1.5 ULN, serum creatinine ≤ 1.5 ULN and endogenous creatinine clearance rate ≥ 40mL/min, ALT ≤ 5ULN, AST ≤ 5ULN, total bilirubin ≤ 2.5ULN, prothrombin time extension ≤ 4s;
14\. The women of childbearing age must carry out serum pregnancy test within the screening period and 14 days before starting the study medication, and the result is negative. They are willing to use reliable methods of contraception during the test period (within 12 months (M12) after cell infusion); For male subjects whose partners are women of childbearing age, they should have undergone sterilization or agree to use reliable methods of contraception during the trial
15\. Be able to understand and sign the informed consent form
Exclusion Criteria
2. HCV-RNA, HIV antibody or syphilis antibody are positive;
3. Any uncontrollable active infection, including but not limited to active tuberculosis;
4. Have received systemic steroids equivalent to\>15 mg prednisone within 2 weeks before single collection, except inhaled steroids;
5. Allergies to immunotherapy and related drugs, previous severe allergies β- Allergy to lactam antibiotics;
6. Previous or current hepatic encephalopathy;
7. At present, there is ascites with clinical significance, which is defined as: ascites with positive signs on physical examination or ascites that need to be controlled by intervention (such as puncture or drug therapy) (only those with ascites shown on imaging without intervention can be included);
8. Imaging examination results: the proportion of liver being replaced by tumor ≥ 50%, or portal trunk tumor thrombus, or tumor thrombus invading mesenteric vein/inferior vena cava;
9. Central nervous system metastasis and diseases of central nervous system with clinical significance;
10. At present, there is a heart disease that needs treatment or hypertension that is judged by the researcher to be poorly controlled (systolic blood pressure\>160mmHg or diastolic blood pressure\>100mmHg);
11. Patients with known active autoimmune diseases need to be treated with immunosuppressants including biological agents;
12. Patients with a history of organ transplantation or waiting for organ transplantation (including liver transplantation);
13. Have received treatment for the study disease within 2 weeks before single collection, including but not limited to surgical treatment, interventional treatment, radiotherapy, chemotherapy and immunotherapy;
14. Received targeted GPC3 treatment, TCR-T treatment and CAR-T treatment in the past month;
15. Being treated with anti PD-1/PD-L1 monoclonal antibody in the past 28 days;
16. Other incurable malignant tumors in the past 5 years or at the same time, excluding cervical carcinoma in situ and skin basal cell carcinoma;
17. Other serious diseases that may restrict the subjects from participating in this trial (such as diabetes under poor control (HbA1c\>7% after treatment), severe cardiac insufficiency (LVEF\<45%), myocardial infarction or unstable arrhythmia or unstable angina pectoris in the last 6 months, pulmonary embolism, chronic obstructive pulmonary disease, interstitial lung disease Pulmonary function test FEV1 accounts for less than 60% of the estimated value, gastric ulcer, history of gastrointestinal bleeding disease or clear gastrointestinal bleeding tendency);
18. The investigator assessed that the patient was unable or unwilling to comply with the requirements of the study protocol.
40 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shenzhen University General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
YuLi
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Li Yu, Dr
Role: PRINCIPAL_INVESTIGATOR
Shenzhen University General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Li Yu
Shenzhen, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HEM-ONCO-023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.